Topoisomerase I inhibitor 7 (Compound 8) 是有效的Topoisomerase I 抑制剂。Topoisomerase I inhibitor 7 显著抑制肿瘤生长(高达 79%)。在接受 P388 淋巴瘤移植的小鼠模型中,Topoisomerase I inhibitor 7延长了小鼠寿命(153%)。
Topoisomerase I inhibitor 5 is an efficient inhibitor of topoisomerase I, with an IC50 value. It effectively disrupts DNA and inhibits the activity of topoisomerase I. Moreover, it can induce apoptosis in MCF-7 cells and arrest the cell cycle at the G1 phase. Topoisomerase I inhibitor 5 also exhibits potency in reversing P-gp-mediated resistance to Adriamycin [1].
Topoisomerase I II inhibitor 3 (化合物7) 是拓扑异构酶 I (Topo I)和 II (Topo II)的有效双抑制剂。 通过抑制 PI3K Akt mTOR 信号通路,Topoisomerase I II inhibitor 3抑制细胞增殖、侵袭和迁移,诱导细胞凋亡(apoptosis)。Topoisomerase I II inhibitor 3 在肝癌中具有研究价值。
Topoisomerase I inhibitor 4 (compound 7a) is a potent inhibitor of topoisomerase I activity. It effectively inhibits the proliferation of various cancer cell lines including HepG2, A549, MCF-7, and HeLa, with IC50 values of 1.20 μM, 2.09 μM, 1.56 μM, and 1.92 μM, respectively. Thus, Topoisomerase I inhibitor 4 holds promise for cancer research applications [1].
Topoisomerase I II inhibitor 2 (compound 1a) 可显著抑制小鼠模型中的异种移植肿瘤的生长,可用于肝癌治疗。Topoisomerase I II inhibitor 2 是一种DNA 拓扑异构酶 I II 的双重抑制剂。Topoisomerase I II inhibitor 2 是有效的拓扑异构酶抑制剂,对LM9 细胞和Huh7 细胞的 IC50值分别为 6.83 μM 和9.82 μM 。
Doxorubicin hydrochloride (Adriamycin) 属于蒽环类抗生素,是人类 DNA 拓扑异构酶 I II 抑制剂 (IC50=0.8 2.67 μM)。Doxorubicin hydrochloride 具有细胞毒性和抗肿瘤活性。Doxorubicin hydrochloride 可降低 AMPK 及其下游靶蛋白乙酰辅酶 A 羧化酶的磷酸化,还可诱导凋亡和自噬。
Diflomotecan (BN 80915) is a potent, orally active topoisomerase I inhibitor that displays enhanced plasma stability and superior preclinical anti-tumor activity relative to other established compounds.
MC-SN38 is a drug-linker conjugate that pairs the potent microtubule-disrupting agent SN38 with a non-cleavable MC linker, designed for use in antibody drug conjugates (ADCs). SN38, the active metabolite of the Topoisomerase I inhibitor Irinotecan, works by inhibiting DNA synthesis and inducing DNA single-strand breaks.